958 results on '"Nickoloff, Brian J."'
Search Results
2. 732 - EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations.
3. The Immunobiology of Dermis
4. Dermal Immune System
5. Data from A Phase 2a Study of Topical Perillyl Alcohol Cream for Chemoprevention of Skin Cancer
6. Data from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
7. Supplementary Figure S1 from Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma
8. Data from Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma
9. Supplementary Figure 1 from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
10. Supplementary Figure 2 from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
11. Supplementary Figure 4 from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
12. Supplementary Figure Legend from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
13. Perspective on this Article from A Phase 2a Study of Topical Perillyl Alcohol Cream for Chemoprevention of Skin Cancer
14. Supplementary Figure 3 from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
15. Supplementary Figure 2 from Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation
16. Supplementary Table 1 and Figure 4 from Conservation of Genetic Alterations in Recurrent Melanoma Supports the Melanoma Stem Cell Hypothesis
17. Supplementary Table 1 from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
18. Supplementary Figure S3 from Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells
19. Supplementary Figure 1 from Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation
20. Supplementary Figure 4 from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
21. Data from Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation
22. Data from Focal Adhesion Kinase Promotes the Aggressive Melanoma Phenotype
23. Supplementary Figure 6 from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
24. Supplementary Figure 3 from Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation
25. Supplementary Figure 4 from Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation
26. Supplementary Table 1 from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
27. Supplementary Figure 5 from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
28. Supplementary Figure 3 from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
29. Supplementary Methods and Materials, Figure Legends 1-7 from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
30. Data from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
31. Supplementary Methods and Materials from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
32. Supplementary Figure 1 from Focal Adhesion Kinase Promotes the Aggressive Melanoma Phenotype
33. Supplementary Figure 1 from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
34. Supplementary Data 1 from Conservation of Genetic Alterations in Recurrent Melanoma Supports the Melanoma Stem Cell Hypothesis
35. Supplementary Figure Legends 1-2 from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
36. Data from Conservation of Genetic Alterations in Recurrent Melanoma Supports the Melanoma Stem Cell Hypothesis
37. Supplementary Figure 7 from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
38. Supplementary Table 1 from Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation
39. Supplementary Table 2 from Focal Adhesion Kinase Promotes the Aggressive Melanoma Phenotype
40. Supplementary Figure 2 from Focal Adhesion Kinase Promotes the Aggressive Melanoma Phenotype
41. Supplementary Figure 3 from Focal Adhesion Kinase Promotes the Aggressive Melanoma Phenotype
42. Supplementary Figure 5 from Wnt5A Regulates Expression of Tumor-Associated Antigens in Melanoma via Changes in Signal Transducers and Activators of Transcription 3 Phosphorylation
43. Supplementary Figure 2 from Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
44. Supplementary Figure 1 from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
45. Data from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
46. Supplementary Figure 4 from Focal Adhesion Kinase Promotes the Aggressive Melanoma Phenotype
47. Supplementary Figure 2 from Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
48. Immune Response in Human Melanoma after Transfer of an Allogeneic Class I Major Histocompatibility Complex Gene with DNA-Liposome Complexes
49. Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay
50. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.